Bivalent vaccine for brucellosis and tuberculosis
This technology is a dual-purpose vaccine designed to protect against both Brucella and Tuberculosis (TB) simultaneously. Researchers modified a specific, safe strain of Brucella bacteria to act as a delivery vehicle that carries and expresses proteins from the Tuberculosis bacterium. By optimizing the genetic code of the TB proteins to match the Brucella host, the vaccine generates a robust immune response against both pathogens in a single administration. This approach leverages an existing, environmentally safe vaccine platform to address two major infectious diseases at once.
What you could build
A bivalent veterinary vaccine for livestock (cattle, goats, sheep) to prevent Brucellosis and Bovine TB, or a specialized human vaccine for at-risk populations in regions where both diseases are endemic.
Who in Virginia should care
Virginia's significant agricultural sector (cattle) and biodefense-related pharmaceutical companies would be interested in combined animal health solutions.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Sriranganathan NAMMALWAR, Hamzeh AL QUBLAN, Garrett SMITH, Stephen BOYLE, Gerhardt SCHURIG
- Granted
- September 10, 2019
- Status
- Granted patent
- Patent number
- 10406219
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.